Jean-Christophe Leroux
Dr. Jean-Christophe Leroux (born April 27, 1969) is a French-Canadian full professor of Drug Formulation and Delivery at the Institute of Pharmaceutical Sciences at the Swiss Federal Institute of Technology ETH Zürich. His research is mainly focused on broadening the field of drug delivery, and the development of biodetoxification systems for the treatment of metabolite disorders. Additionally, he has made important contributions to the field of biomaterials for use in drug delivery. Education. Leroux trained as a pharmacist at the University of Montreal (Canada), and received his Ph.D. in Pharmaceutical Sciences (1995) from the University  of Geneva (Switzerland). From 1996 to 1997, he was a postdoctoral fellow at University of California, San Francisco. Career. Leroux was appointed professor at the University of Montreal in 1997 where he worked until he joined the ETH Zürich. From 2001 to 2010, he held the Tier 2 Canada research chair in drug delivery. He was the chair of the institute of Pharmaceutical Sciences at the ETH Zürich during 2014–2016, and was appointed as head of the department Leroux has made fundamental and applied contributions to the fields of colloids, biomaterials, and drug delivery. He has published over 250 peer -reviewed manuscripts in top-ranked scientific journals, 14 book chapters and is co-inventor on several patents. Jean-Christophe Leroux is one of the most cited scientists in pharmacy and pharmacology. Leroux was the associate editor of the "European Journal and Pharmaceutics and Biopharmaceutics" from 2006 to 2012, and of the "Journal of Controlled Release" from 2012 to 2017. In 2015, Leroux co-founded the ETH spin-off companies Versantis AG and Inositec AG that are developing drugs for the treatment of hyperammonemia and vascular calcification, respectively. Inositec AG was acquired by Vifor Pharma in Nov-2021 for the development of  treatments against calcification disorders at all stages of chronic kidney disease.